HealthLynked Corp. filings document the regulatory record of a Nevada healthcare technology company whose common stock trades on the OTCQB under HLYK. Securities Act registration statements describe the company, proposed public offering disclosures, share registration mechanics, risk factors, capitalization, and related public-company information.
Current reports on Form 8-K cover material corporate events, including financing arrangements, unregistered equity-related securities, secured convertible debt obligations, executive appointments, and governance changes. The filing record also provides disclosure on capital structure, board and officer matters, related-party financing context, and the company’s reporting status, including the absence of securities registered under Section 12(b) in the cited filings.
HealthLynked Corp. is registering $7,000,000 of common stock in a public offering and 150,000 additional shares for resale by a selling stockholder. The primary sale is expected to price between $4.00 and $6.00 per share, with an assumed 1,400,000 shares at $5.00 for illustrative purposes.
The company estimates net proceeds of about $6.16 million (or $7.14 million with full over-allotment), to fund working capital, capital expenditures, research and development, sales and marketing, and repayment of specific debts. A significant portion of related-party convertible debt held by CEO Dr. Michael Dent is assumed to convert into equity for Nasdaq listing purposes.
HealthLynked reports cash of $37,136, a working capital deficit of $5.46 million and an accumulated deficit of $50.54 million as of December 31, 2025, leading to substantial doubt about its ability to continue as a going concern. Management believes proceeds from this offering, if completed, will help address liquidity concerns for at least the next twelve months.
HealthLynked Corp., a Nevada-based healthcare technology company, reports its annual results and outlines a shift from owning clinics toward a predominantly digital, technology-enabled model. The company operates three divisions: Digital Healthcare (its cloud-based HealthLynked Network with AI-assisted tools, telemedicine, concierge services, Oohvie, and a prescription discount program), Health Services (now a single functional medicine practice slated for divestiture), and Medical Distribution (MedOfficeDirect, an asset-light online medical supplies marketplace).
Management discloses substantial doubt about the company’s ability to continue as a going concern, citing $37,136 in cash, a working capital deficit, significant accumulated losses, and the need for additional financing in the first half of 2026. The filing highlights heavy competition from large digital health, EMR, telemedicine, and big tech players, regulatory complexity across healthcare, privacy and billing laws, and reliance on Amazon Web Services. It also notes sizeable related-party convertible debt owed to CEO Dr. Michael Dent, which may create dilution and conflict-of-interest risks. To support payer-integration and value-based care pilots, HealthLynked entered an advisory arrangement with Palm Beach Accountable Care Organization in December 2025, though no revenue from such initiatives is assured.
HealthLynked Corp. is conducting a primary offering of up to 1,750,000 shares of common stock for $7,000,000 under an S-1 registration statement. The assumed price range is $4.00–$6.00 per share, with a base offering of 1,400,000 shares plus a 210,000-share over-allotment option.
The company’s stock currently trades on the OTCQB as “HLYK” and the offering is conditioned on approval for listing on Nasdaq; if Nasdaq does not approve the listing, the offering will not close. At a $5.00 midpoint, net proceeds are estimated at $6,160,000, to be used for working capital, capital expenditures, research and development, sales and marketing, and repayment of indebtedness.
As of September 30, 2025, HealthLynked had $10,911 in cash, a $5,201,336 working capital deficit and a $50,768,392 accumulated deficit, creating substantial doubt about its ability to continue as a going concern. The offering, together with the assumed conversion of $4,500,000 of related-party convertible debt into 1,058,824 shares at $4.25 per share, would turn a shareholders’ deficit of $(5,433,415) into pro forma equity of $5,226,585.
Common shares outstanding are expected to rise from 2,881,104 before the offering to 4,281,104 after the base deal, or 4,491,104 if the over-allotment is fully exercised, at the assumed price. New investors will experience immediate dilution; at a $5.00 price, pro forma net tangible book value would be $0.98 per share, implying dilution of $4.02 per share to new purchasers.
HealthLynked Corp. entered into a related-party financing by issuing a senior secured convertible promissory note with principal of $5,715,811.98 to the Mary S. Dent Gifting Trust, which is controlled by its CEO and Chairman, Dr. Michael Dent.
The new note consolidates prior obligations, including earlier promissory notes with principal of $4,338,191.70 and accrued interest of $737,180.26, undocumented advances of $339,840.02, and $300,600.00 of unpaid 2017 compensation. It carries 12% annual interest, rising to 18% upon uncured default, matures on February 2, 2029, and is secured by a first-priority lien on all company assets. The note is optionally convertible into common stock at $4.25 per share and was issued in a private, unregistered transaction relying on Section 4(a)(2) and Regulation D exemptions.
HealthLynked Corp. reported several leadership changes. The company appointed Duncan McGillivray as Chief Operating Officer effective December 8, 2025. He has more than 30 years of experience in healthcare, capital markets, and large-scale project finance, including work on a targeted $40M construction project in Miami and helping close over $200 million of funded projects for community health facilities.
His initial base salary is $120,000 per year, increasing to $150,000 if the company successfully uplists to the Nasdaq Capital Market, and he will receive up to 180,000 restricted stock units, split between time-based and uplisting-based vesting. Effective December 1, 2025, HealthLynked also expanded its Board from six to eight members and appointed Jason Bishara and Chris G. Pulos as non‑employee directors, each receiving annual compensation of $20,000 in common stock vesting quarterly over one year.
HealthLynked Corp. (HLYKD) reported lower sales and continued losses for the quarter ended September 30, 2025. Total revenue was $388,545 versus $590,124 a year earlier, as patient service, subscription, and product revenue all declined. For the first nine months of 2025, revenue was $1,755,113 compared with $2,389,434 in the prior-year period.
The company posted a quarterly net loss of $851,800 and a nine‑month net loss of $2,603,777, though both were smaller than the prior year. Operating expenses fell year over year, helped by the absence of a $716,000 impairment charge recorded in 2024 and lower practice and overhead costs.
HealthLynked’s balance sheet remains strained. As of September 30, 2025, cash was $10,911, total assets were $1,764,557, and shareholders’ deficit widened to $5,433,415. Current liabilities of $6,744,301 included significant related‑party convertible debt, third‑party notes, and lease obligations. Management disclosed a substantial doubt about the company’s ability to continue as a going concern through November 19, 2026 without additional capital.
During the period, HealthLynked executed a 1‑for‑100 reverse stock split, reducing outstanding common shares from 284,750,832 to 2,847,873, and later agreed to sell its BTG physical therapy practice assets for $125,000 in cash.